(NASDAQ: MRNA) stock soared during the pandemic as investors bet on the company's coronavirus vaccine candidate. Since then, the biotech launched a vaccine, followed by updated boosters, and generated billions of dollars in earnings. But the stock-price performance has stumbled in the post-pandemic world, and investors are worried about Moderna's reliance on its only product.

The company may not be a one-product company for long, though. It may not even be a two-product company for long. The company has big plans for the next several years and has set out a roadmap to reach its goals.

Moderna offered investors more details about its projects and prospects this week during its annual R Day. If you're worried about Moderna, one number may completely change your mind.

Continue reading

Source Fool.com